The biotechnology industry, and health care overall, is generally somewhat protected from broader economic concerns, but the war in Ukraine adds to an existing sense of uncertainty due to rising inflation, ongoing labor shortages and continued supply constraints that were already troubling investors who have moved money out of the industry, Deloitte chief global economist Ira Kalish said in a recent fireside chat hosted by Biocom California.
Global Uncertainty Is Impacting Deal-Making, Investment Decisions
Deloitte Economist Considers How Macroeconomic Issues Affect Biotech
Deloitte chief global economist Ira Kalish said in a Biocom webinar that the war in Ukraine increased existing macroeconomic uncertainty, which is keeping businesses and investors from deploying capital.
More from Deals
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
More from Business
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.